GlaxoSmithKline sues Lupin over Combivir patent
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlinehas filed a suit against Lupinin the US district court of Delaware claiming infringement of its patent for the anti-AIDS drug Combivir (lamivudine 150mg and zidovudine 300mg). The US FDA had in September 1997 granted approval to GSK to sell Combivir tablets. GSK claims that it will be irreparably harmed by Lupin's infringing activities unless enjoined by court. It has claimed monetary relief should Lupin manufacture and sell the product in the US or import the product before the expiry of the patent. Lupin's managing director, Dr Kamal Sharma, said that Lupin had filed a paragraph IV certification for GSK's patent for Combivir and is confident of the merit of its case. Lupin said that it is committed to bringing down healthcare costs worldwide through world-class quality generics and play a critical role in enhancing access to medicine for a larger patient population.
You may also be interested in...
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Astellas CStO Pearson: We’re Not Short Of Opportunities To Compensate For LOEs
Astellas’ chief strategy officer, Adam Pearson, talks to Scrip about the company’s launch execution thrust for key therapies ahead of the loss of exclusivity for Xtandi and also deal-making appetite and choices, including the Iveric Bio buyout and walking away from the collaboration with Cartesian Therapeutics.